16 April 2025
Champalimaud Foundation is proud to share that the Champalimaud Research Programme has received the highest possible rating – Excellent, with 5 out of 5 points across all evaluation criteria – in the provisional results of the 2023/2024 R&D Units Evaluation, recently released by the Portuguese Foundation for Science and Technology (FCT).
This recognition affirms the dedication and collaborative effort of countless individuals over the years in building the diverse and sophisticated infrastructure necessary to support a world-class, cutting-edge biomedical research centre. As the Head of this FCT R&D Unit Joe Paton puts it, “It also feels like an endorsement of the integrative approaches we take to understanding the circuit, systems, and computational principles underlying behaviour, the broader, multi-system perspective on organismal biology that defines much of the research developed at CR, as well as our vision for how to apply the knowledge created by such fundamental scientific pursuits to improving health. It underscores the growing role of computational methods in unlocking insights into such complex systems.”
This is a moment of celebration and pride – a testament to the vision, passion, and excellence that define our community. At the same time, it energises us to push forward with renewed commitment to groundbreaking, high-impact research.
This achievement reflects the dedication and outstanding contributions of the entire CR community.
The FCT evaluation assessed the scientific and technological activities carried out between 1 January 2018 and 31 December 2023, alongside the proposed objectives, strategies, activity plan, and organisational model for the 2025-2029 period. The process brought together over 315 international experts from academic and scientific institutions across 35 countries, organised into 29 disciplinary panels.
The provisional results of the evaluation of R&D Units under the Multiannual Financing Programme 2023/2024 can be consulted here. According to these results, CR is set to receive 8.9M€ in funding for the 2025-2029 period.
